XVIII CONGRESSO NAZIONALE AIOM - ROMA, October 28th-30th 2016

Leonid’s product and impacts

• RealQuant® Lung Fusion Genes, medical device validated for in vitro diagnostic use under the 98/79/EC directive.
• One test for multiple biomarkers detection and quantification (ALK, ROS1 and RET gene rearrangements in the same reaction) --> reduction of costs.
• Identification of the main fusion genes in the same well.
• Standardized results without personal interpretation and simplification of the medical report thanks to a dedicated software for secondary analysis on Nanostring® output data --> reduction of data decoding errors.
• Easy-of-use (only 4 pipetting steps) --> reduction of hands-on-time and manual errors. 
• Higher throughput (up to 10 samples per run).
• Faster workflow (from FFPE tissue to data in less than 2 days).
• Quality control of pre-analytical and analytical steps.
• Performance validated in a multicenter clinical study at Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa - Azienda Ospedaliero Universitaria Pisana (Pisa) and at Laboratorio di Bioscienze, Diagnostica Molecolare di III livello - Biomarcatori e Medicina Personalizzata, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS (Meldola).